Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah. more
Time Frame | CLNN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -1.05% | -3.72% | -0.05% |
1-Month Return | 6.82% | -1.85% | 2.75% |
3-Month Return | -15.92% | -11.4% | 7.4% |
6-Month Return | -36.49% | -4.41% | 10.47% |
1-Year Return | -53% | 4.13% | 27.57% |
3-Year Return | -95.46% | 0.3% | 29.56% |
5-Year Return | -97.74% | 36.62% | 89.3% |
10-Year Return | 234900% | 106.81% | 206.09% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 206.00K | 723.00K | 473.00K | 654.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":28.49,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":65.42,"profit":true},{"date":"2023-12-31","value":90.46,"profit":true}] |
Cost of Revenue | 900.00K | 65.00K | 289.00K | 26.00K | 121.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":7.22,"profit":true},{"date":"2021-12-31","value":32.11,"profit":true},{"date":"2022-12-31","value":2.89,"profit":true},{"date":"2023-12-31","value":13.44,"profit":true}] |
Gross Profit | (900.00K) | 141.00K | 434.00K | 447.00K | 533.00K | [{"date":"2019-12-31","value":-168.86,"profit":false},{"date":"2020-12-31","value":26.45,"profit":true},{"date":"2021-12-31","value":81.43,"profit":true},{"date":"2022-12-31","value":83.86,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | - | 68.45% | 60.03% | 94.50% | 81.50% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":72.43,"profit":true},{"date":"2021-12-31","value":63.52,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":86.24,"profit":true}] |
Operating Expenses | 15.73M | 17.14M | 45.71M | 45.78M | 41.07M | [{"date":"2019-12-31","value":34.37,"profit":true},{"date":"2020-12-31","value":37.45,"profit":true},{"date":"2021-12-31","value":99.85,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":89.72,"profit":true}] |
Operating Income | (16.33M) | (17.00M) | (45.28M) | (45.33M) | (40.54M) | [{"date":"2019-12-31","value":-1633200000,"profit":false},{"date":"2020-12-31","value":-1700400000,"profit":false},{"date":"2021-12-31","value":-4527600000,"profit":false},{"date":"2022-12-31","value":-4533000000,"profit":false},{"date":"2023-12-31","value":-4054000000,"profit":false}] |
Total Non-Operating Income/Expense | 89.00K | 393.00K | 35.76M | 14.42M | (13.52M) | [{"date":"2019-12-31","value":0.25,"profit":true},{"date":"2020-12-31","value":1.1,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":40.33,"profit":true},{"date":"2023-12-31","value":-37.81,"profit":false}] |
Pre-Tax Income | (16.16M) | (18.87M) | (10.17M) | (29.92M) | (49.50M) | [{"date":"2019-12-31","value":-1615500000,"profit":false},{"date":"2020-12-31","value":-1887100000,"profit":false},{"date":"2021-12-31","value":-1016800000,"profit":false},{"date":"2022-12-31","value":-2991800000,"profit":false},{"date":"2023-12-31","value":-4950400000,"profit":false}] |
Income Taxes | 115.00K | 406.00K | (428.00K) | (14.64M) | 1.54M | [{"date":"2019-12-31","value":7.48,"profit":true},{"date":"2020-12-31","value":26.41,"profit":true},{"date":"2021-12-31","value":-27.84,"profit":false},{"date":"2022-12-31","value":-952.37,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (16.27M) | (19.28M) | (9.74M) | (15.28M) | (51.04M) | [{"date":"2019-12-31","value":-1627000000,"profit":false},{"date":"2020-12-31","value":-1927700000,"profit":false},{"date":"2021-12-31","value":-974000000,"profit":false},{"date":"2022-12-31","value":-1527900000,"profit":false},{"date":"2023-12-31","value":-5104110500,"profit":false}] |
Income From Continuous Operations | (16.16M) | (19.28M) | (9.74M) | (29.92M) | (40.38M) | [{"date":"2019-12-31","value":-1615500000,"profit":false},{"date":"2020-12-31","value":-1927700000,"profit":false},{"date":"2021-12-31","value":-974000000,"profit":false},{"date":"2022-12-31","value":-2991800000,"profit":false},{"date":"2023-12-31","value":-4038500000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (16.27M) | (19.28M) | (9.74M) | (15.28M) | (49.50M) | [{"date":"2019-12-31","value":-1627000000,"profit":false},{"date":"2020-12-31","value":-1927700000,"profit":false},{"date":"2021-12-31","value":-974000000,"profit":false},{"date":"2022-12-31","value":-1527900000,"profit":false},{"date":"2023-12-31","value":-4950400000,"profit":false}] |
EPS (Diluted) | (0.20) | (0.23) | (0.39) | (0.46) | (0.52) | [{"date":"2019-12-31","value":-19.59,"profit":false},{"date":"2020-12-31","value":-23,"profit":false},{"date":"2021-12-31","value":-39,"profit":false},{"date":"2022-12-31","value":-46,"profit":false},{"date":"2023-12-31","value":-52,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CLNN | |
---|---|
Cash Ratio | 0.61 |
Current Ratio | 0.83 |
Quick Ratio | 0.82 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CLNN | |
---|---|
ROA (LTM) | -41.71% |
ROE (LTM) | -289.66% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CLNN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.13 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.13 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CLNN | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 89.37 |
P/B | 7.83 |
Price/FCF | NM |
EV/R | 113.39 |
EV/Ebitda | NM |
Clene Inc. (CLNN) share price today is $4.7
Yes, Indians can buy shares of Clene Inc. (CLNN) on Vested. To buy Clene Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CLNN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Clene Inc. (CLNN) via the Vested app. You can start investing in Clene Inc. (CLNN) with a minimum investment of $1.
You can invest in shares of Clene Inc. (CLNN) via Vested in three simple steps:
The 52-week high price of Clene Inc. (CLNN) is $12. The 52-week low price of Clene Inc. (CLNN) is $3.82.
The price-to-earnings (P/E) ratio of Clene Inc. (CLNN) is
The price-to-book (P/B) ratio of Clene Inc. (CLNN) is 7.83
The dividend yield of Clene Inc. (CLNN) is 0.00%
The market capitalization of Clene Inc. (CLNN) is $39.50M
The stock symbol (or ticker) of Clene Inc. is CLNN